Benign prostatic hyperplasia: Patients' perception of medical treatment and their expectations. Results of a French survey involving patients treated with finasteride;Hypertrophie bénigne de la prostate: Attentes des patients et perception du traitement. Résultats d'une enquête menée en France auprès de patients traités par finastéride

Therapie

Volumn 57, Issue 5, 2002, Pages 473-483

  Teillac, P ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Benign prostatic hyperplasia; Finasteride

Indexed keywords

FINASTERIDE;

ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPECTATION; FRANCE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RISK ASSESSMENT; SYMPTOM; TREATMENT OUTCOME;

AGED; DATA COLLECTION; ENZYME INHIBITORS; FINASTERIDE; FRANCE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSTATIC HYPERPLASIA; QUESTIONNAIRES;

EID: 17144450483     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Andersen JT. Prostatism, clinical, urodynamic and radiological aspects. Neurol Urodyn 1982; 1: 241-93
2. Calais Da Silva F, Marquis P, Deschaseaux P, et al. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Eur Urol 1997; 31: 272-80
3. Barry MJ, Fowler FJ Jr, Bin L, et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 1997; 157: 10-4
4. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Clin Pract Guidel 1994; 8: 7-14
5. Résumé des caractéristiques du produit Chibro-Proscar®
6. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185-91
7. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5α reductase, suppresses prostatic dihydrosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505-8
8. Boyle P, Gould AL, Roehrbom CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
9. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338 (9): 557-63
10. Stoner E, Members of the Finasteride Study Group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284-93
11. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995; 46: 631-7
12. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J 1996; 155: 1251-9